Načítá se...
MET IHC is a Poor Screen for MET Amplification or MET exon 14 mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium
BACKGROUND: MET amplification and MET exon 14 alterations (METex14) in lung cancers impart sensitivity to MET kinase inhibitors. Fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), and IHC, have been used to evaluate MET dependency. Here, we determined the association of MET...
Uloženo v:
| Vydáno v: | J Thorac Oncol |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6708730/ https://ncbi.nlm.nih.gov/pubmed/31228623 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2019.06.009 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|